Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366881 · ClinicalTrials.gov registry record
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
A clinical trial of Breast Cancer and Colorectal Cancer, sponsored by Adela.
- Recruiting
- Registry status
- 7,000
- Enrollment target
- 17
- Study locations
NCT05366881 is a study of Breast Cancer and Colorectal Cancer that is actively recruiting participants, run by Adela. The registered enrollment target is 7,000 participants, above the 2,798-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (150% higher). The trial reports 17 study locations across 11 states.
The verdict
NCT05366881, a study of Breast Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Adela.
- RECRUITING
- Registry status
- 7,000 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.
Conditions Studied
Study Locations (17)
Kentucky
- Baptist Corbin - Corbin
- Baptist Hardin - Elizabethtown
- Baptist Lexington - Lexington
- Baptist Paducah - Paducah
Minnesota
- Allina Health Cancer Institute - Minneapolis
- Mayo Clinic - Rochester
South Carolina
- Medical University of South Carolina - Charleston
- McLeod Health - Florence
Tennessee
- Baptist (BHMCC) - Memphis
- Vanderbilt-Ingram Cancer Center - Nashville
California
- City of Hope - Duarte
Florida
- Miami Cancer Institute - Miami
Georgia
- North Georgia Health System - Gainesville
Indiana
- Baptist Floyd - New Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,000 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2027-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05366881
The ClinicalTrials.gov registry entry for NCT05366881 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 7,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,798-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (150% higher). The listed sponsor is Adela, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05366881 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Kentucky, Minnesota, South Carolina.
Frequently Asked Questions
What is clinical trial NCT05366881 about?
NCT05366881 is a clinical study titled "cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease". This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastr...
What is the current status of trial NCT05366881?
This trial is currently recruiting. The enrollment target is 7,000 participants. The study started on 2022-05-03. Estimated completion is 2027-03.
What conditions does trial NCT05366881 study?
This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Endometrial Cancer, Bladder Cancer.
Who is sponsoring clinical trial NCT05366881?
This trial is sponsored by Adela, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05366881 being conducted?
This trial has 17 study locations across California, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.